Sections
Log in
Top News
U.S. News World News Featured Voices
Odd News
Entertainment
Movies Music TV
Sports
Soccer NFL NBA MLB NHL Golf Horse Racing Tennis Col. Football Col. Basketball
Photos
News Entertainment Sports Features Archives
More...
Defense Featured Science Health Archive Almanac
About Feedback
About Feedback
Search
Trending
National emergency
Netflix
SpaceX
Venezuela
Mark Consuelos
Jussie Smollett
Michael Cohen
Biggest bee
Dog church
TXT
JAXA
Health News
Jan. 18, 2019 / 10:40 AM

Generic version of epilepsy drug Sabril approved by FDA

By
HealthDay News
The FDA has approved a generic version of the drug Sabril, which is used to prevent complex seizures in adults and children 10 and older with epilepsy. Photo by nosheep/Pixabay

The first generic version of Sabril, or vigabatrin, has been approved by the U.S. Food and Drug Administration to prevent complex partial seizures in adults and children 10 and older with epilepsy.

"The availability of high-quality generic alternatives of critically important medicines, once the period of patent protection or exclusivity has ended on the brand drug, helps advance access and saves consumers billions of dollars each year," said FDA Commissioner Dr. Scott Gottlieb.

A complex partial seizure originates in a certain area of the brain, typically lasting 30 seconds to 90 seconds. Disorientation, confusion, fatigue and even loss of consciousness may follow, the FDA said in a news release.

The agency repeated prior assertions that generic equivalents are held to the same vigorous manufacturing standards as brand-name drugs, and have been deemed equally safe, effective and chemically equivalent.

Vigabatrin's label includes a boxed warning of the possibility of permanent vision loss. The drug's most common side effects include dizziness, fatigue, insomnia, involuntary eye movement, blurred vision, memory impairment and weight gain. A more serious adverse reaction may be suicidal thoughts or actions, the FDA said.

Approval of generic vigabatrin tablets was granted to Teva Pharmaceuticals USA, whose parent company is based in Israel.

More information

The FDA has more about this approval.

Copyright © 2019 HealthDay. All rights reserved.

Read More

Using epilepsy drug valproate during pregnancy tied to kid's ADHD Researchers develop two methods to treat seizures in Dravet syndrome First FDA-approved drug containing marijuana extract goes on sale in U.S.
  • Topics
  • Food and Drug Administration
Follow us on Facebook, Twitter and Instagram for more UPI news and photos.

Trending Stories

Report: The number of cancer survivors grows as oncologists dwindle
Alzheimer's breakthrough may come from bone marrow experiment with mice
U.S. women have lower blood pressure, more obesity than men, study says
Teens view anxiety, depression as biggest problems in lives, study says
Study links sleep apnea, daytime drowsiness to heart disease

Photo Gallery

 
The 1975, Dua Lipa walk Brit Awards red carpet

Latest News

Famous birthdays for Feb. 22: Kyle MacLachlan, Julie Walters
On This Day: Lee Petty wins first Daytona 500
UPI Almanac for Friday, Feb. 22, 2019
Japan battles worst measles outbreak in 10 years
Trump administration ends fuel efficiency talks with California
 
Back to Article
/
Back to top
About UPI Contact Feedback Advertisements Submit News Tips
Copyright © 2019 United Press International, Inc. All Rights Reserved.
Terms of UsePrivacy Policy